Zusammenfassung der Ressource
Bronchiolitis
- epidemiology
- commonest serious respiratory infection of infancy
- 2-3% of all infants admitted to hospital/ yr during annual winter epidemics
- 90% of cases are 1-9 mths old
- rare after 1 year of age
- pathogen
- virus
- RSV
- causes 80% of cases
- highly infectious
- human metapneumovirus
- parainfluenza virus
- rhinovirus
- adenovirus
- influenza
- bacteria
- Mycoplasma pneumoniae
- clinical features
- coryzal sx
- followed by
- dry cough
- increasing breathlessness
- feeding difficulty
- assoc w/ increasing dyspnoea
- often reason for hosp admission
- on examination
- sharp dry cough
- tachypnoea
- hyperinflation of chest
- prominent sternum
- liver displaced downwards
- fine end-inspiratory crackles
- +/- high pitched wheezes- exp> insp
- tachycardia
- cyanosis or pallor
- subcostal & intercostal recession
- complications
- serious
- recurrent apnoea
- esp in young infants
- < 4 mths old
- high risk groups for severe bronchiolitis
- premature infants
- who developed bronchopulmonary dysplasia
- w/ underlying lung disease
- Cystic fibrosis
- w/ congenital heart disease
- Ix
- nasopharyngeal secretions (aspirate?)
- PCR
- ID resp viruses
- CXR
- unnecessary in straightforward cases
- rarely helpful in bronchiolitis
- signs
- hyperinflation of lungs
- due to small airways obstruction
- flattening of diaphragm
- air trapping
- focal atelectasis
- horizontal ribs
- increased hilar bronchial markings
- pulse oximetry
- continuous monitoring of arterial O2 sats
- blood gas analysis
- from capillary sample
- done only in severe disease
- to ID hypercarbia when additional ventilatory support is needed
- Mx
- supportive
- humidified O2
- via nasal cannulae
- conc needed determined by pulse oximetry
- monitoring
- for apnoea
- fluids
- NG
- IV
- ventilation
- assisted
- nasal CPAP
- facemask CPAP
- full
- infection control
- Prognosis
- most recover from acute infection within 2 weeks
- 1/2 will have recurrent episodes of cough and wheeze
- rare
- ff adenovirus infection
- bronchiolitis obliterans
- permanent damage to airways
- prevention
- palivizumab
- monoclonal antibody to RSV
- monthly i.m. injection
- reduces risk of hosp admissions in high-risk preterm infants
- costly
- multiple i.m injections needed